• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Aptar Pharma banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Iconovo announces expansion of deal with Amneal on generic Symbicort and launch of pharma division

DPI developer Iconovo has announced that its development deal with Amneal for a generic version of Symbicort has been amended to add US and Chinese marketing rights for Amneal and Nordic region marketing rights for Iconovo. Acquisition of the Nordic marketing rights also marks the launch of a new division of Iconovo, Iconovo Pharma. The original deal included … [Read more...] about Iconovo announces expansion of deal with Amneal on generic Symbicort and launch of pharma division

Pulmatrix says Cipla has breached a 2019 development agreement for Pulmazole intraconazole DPI

A month after regaining rights to PUR1800 and other inhaled narrow spectrum kinase inhibitors from Johnson & Johnson, Pulmatrix has announced that it may also reacquire the rights to its Pulmazole intraconazole DPI (PUR 1900). According to the company's business update, Pulmatrix recently notified Cipla that Cipla breached a 2019 development and commercialization … [Read more...] about Pulmatrix says Cipla has breached a 2019 development agreement for Pulmazole intraconazole DPI

Vectura to develop inhaled formulation of Inspira candidate for the treatment of COVID-19

Inhalation CDMO Vectura has signed an agreement with Inspira Pharmaceuticals to develop an inhaled formulation of a plant extract Inspira is developing for the treatment of COVID-19, the company said. Vectura will create a version of the IPX formulation to be delivered via Vectura's Fox vibrating mesh nebulizer for Phase 1 trials. Inspira is looking to raise £350,000 … [Read more...] about Vectura to develop inhaled formulation of Inspira candidate for the treatment of COVID-19

Glenmark launches Ryaltris-AZ nasal spray in India

Glenmark Pharmaceuticals has announced the launch of Ryaltris-AZ mometasone furoate / azelastine nasal spray for the treatment of allergic rhinitis in India, touting the low cost of the nasal spray compared to similar products. According to Glenmark, Ryaltris-AZ is priced at slightly less than half the cost of "the average price of the top 10 brands of the similar … [Read more...] about Glenmark launches Ryaltris-AZ nasal spray in India

Hikma re-starts launch of its generic version of Advair Diskus

Hikma Pharmaceuticals said that the FDA has approved an amendment to the company's ANDA for its generic version of Advair Diskus fluticasone propionate / salmeterol DPI, and the company has subsequently restarted the launch of the inhaler. The FDA initially approved the ANDA in December 2020, and the company said that it was launching the DPI at that time. Hikma … [Read more...] about Hikma re-starts launch of its generic version of Advair Diskus

NeuroRx and Relief Therapeutics publicly air disputes over Zyesami collaboration agreement

NeuroRx and Relief Therapeutics have each issued press releases enumerating disagreements between the companies regarding development of Zyesami aviptadil (RLF-100), a synthetic vasoactive intestinal peptide. The two companies are partnered on development of the formulation for the treatment of acute respiratory distress syndrome caused by COVID-19, for both … [Read more...] about NeuroRx and Relief Therapeutics publicly air disputes over Zyesami collaboration agreement

Virpax says MMS019 nasal spray inhibits viral replication in pre-clinical study

Virpax Pharmaceuticals announced that a study of its MMS019 powder "masking spray" in mice demonstrated "a marked inhibition of viral replication in the mouse nasal passages" for mice infected with SARS-CoV-2 and then given MMS019 intranasally for 6 days. Virpax licensed MMS019 from Nanomerics in August 2020 and is developing the formulation for the prevention of … [Read more...] about Virpax says MMS019 nasal spray inhibits viral replication in pre-clinical study

GH Research raises $125 million for development of inhaled 5-MeO-DMT

GH Research Ireland has closed a $125 million Series B financing round to fund development of its GH001 inhaled 5-MeO-DMT, the company announced. 5-MeO-DMT is psychedelic found in the venom of certain toads. GH is currently developing GH001 for the treatment of treatment resistant depression, and according to the announcement, "The company's goal is to administer … [Read more...] about GH Research raises $125 million for development of inhaled 5-MeO-DMT

Pulmatrix regains rights to its inhaled narrow spectrum kinase inhibitors from J&J

Johnson & Johnson has decided not to exercise an option acquired in a 2020 agreement with Pulmatrix for development and commercialization of Pulmatrix's portfolio of inhaled narrow spectrum kinase inhibitors (NSKIs), including PUR1800. J&J's Lung Cancer Initiative had been interested in developing the dry powder formulation for lung cancer … [Read more...] about Pulmatrix regains rights to its inhaled narrow spectrum kinase inhibitors from J&J

AIM ImmunoTech says early results from Phase 1 safety study of intranasal Ampligen are positive

AIM ImmunoTech has announced that it will definitely advance an intranasal formulation of its Ampligen rintatolimod into a Phase 2 trial after the initial dose tested in a Phase 1 study showed no safety problems. The company announced initiation of the Phase 1 study, which is set to enroll 40 healthy subjects, in March 2021. The Phase 1 study began with a 75 μg dose … [Read more...] about AIM ImmunoTech says early results from Phase 1 safety study of intranasal Ampligen are positive

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 36
  • Page 37
  • Page 38
  • Page 39
  • Page 40
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews